In vitro assay-assisted treatment selection for women with breast or ovarian cancer.
The selection of chemotherapy for women with breast or ovarian carcinoma has been traditionally based on results from phase III comparative trials that define the most active drugs and drug combinations. This approach has led to a significant prolongation of the lives of these patients. Unfortunately, few patients with advanced stage IV disease are cured using the currently available regimens. In order to improve the selection process for individual patients, various types of in vitro tests that assess the activity of standard drugs on a patient's tumor have been developed over the past five decades. As with bacterial culture and sensitivity tests, significant predictive correlations between in vitro drug-response assays and cancer patient response and survival have been demonstrated. Medicare currently covers in vitro drug-resistance assays. This review discusses the historical development of in vitro drug-response assays and the clinical validation of various technologies currently available to assist the clinician in selecting the optimal therapy for each patient.
Fruehauf
J P
JP
Oncotech Inc., Tustin, California and University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California 92782, USA. johnfruehaut@msn.com
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000266:history / Q000379:methods; D005260:Female; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured